We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
+13.8%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$14.5B
AUM Growth
+$1.96B
Cap. Flow
+$582M
Cap. Flow %
4.02%
Top 10 Hldgs %
31.8%
Holding
146
New
31
Increased
52
Reduced
23
Closed
24

Top Buys

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$319M
2
IMMU
Immunomedics Inc
IMMU
+$296M
3
GOOG icon
Alphabet (Google) Class C
GOOG
+$216M
4
NYT icon
New York Times
NYT
+$130M
5
HLT icon
Hilton Worldwide
HLT
+$129M

Top Sells

Rank Stock Value
1
PPLI
People Inc
PPLI
+$456M
2
WUBA
58.com Inc
WUBA
+$268M
3
CRM icon
Salesforce
CRM
+$181M
4
QGEN icon
Qiagen
QGEN
+$123M
5
CZR
Caesars Entertainment Corporation
CZR
+$97.2M

Sector Composition

Rank Sector Weight
1 Healthcare 44.6%
2 Communication Services 17.58%
3 Technology 8.94%
4 Financials 7.39%
5 Industrials 5.31%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KSU
51
DELISTED
Kansas City Southern
KSU
$71.2M 0.49%
+394,000
New +$68.2M
BRMK
52
DELISTED
Broadmark Realty Capital Inc. Common Stock
BRMK
$70.7M 0.49%
7,170,213
– –
APLS
53
DELISTED
Apellis Pharmaceuticals
APLS
$68.6M 0.47%
2,275,000
+25,000
+1% +$747K
PCG icon
54
PG&E
PCG
$38.8B
$68.5M 0.47%
+7,292,042
New +$67.6M
GBIO
55
DELISTED
Generation Bio
GBIO
$65.5M 0.45%
212,063
+181
+0.1% +$43.3K
SAGE
56
DELISTED
Sage Therapeutics
SAGE
$64.2M 0.44%
1,050,000
+200,000
+24% +$10.1M
EFX icon
57
Equifax
EFX
$22.6B
$62.2M 0.43%
396,484
+141,140
+55% +$23.1M
GRFS
58
Grifois
GRFS
$5.44B
$54.3M 0.38%
3,128,750
+15,528
+0.5% +$274K
KRTX
59
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$54.1M 0.37%
700,000
+125,000
+22% +$10.7M
PTGX icon
60
Protagonist Therapeutics
PTGX
$9.99B
$53.8M 0.37%
2,750,000
+250,000
+10% +$4.69M
ARNA
61
DELISTED
Arena Pharmaceuticals Inc
ARNA
$47.1M 0.33%
629,886
-270,114
-30% -$18M
CYTK icon
62
Cytokinetics
CYTK
$10.7B
$46.5M 0.32%
2,150,000
+650,000
+43% +$15.2M
AMRS
63
DELISTED
Amyris Inc.
AMRS
$40.9M 0.28%
14,000,000
+6,990,473
+100% +$25.6M
ANNX icon
64
Annexon
ANNX
$961M
$40.4M 0.28%
+1,657,261
New +$38.9M
ZGNX
65
DELISTED
Zogenix, Inc.
ZGNX
$40.3M 0.28%
2,250,000
+250,000
+13% +$6.13M
PACB icon
66
Pacific Biosciences
PACB
$420M
$40.1M 0.28%
4,063,770
+1,063,770
+35% +$6.12M
ZYME icon
67
Zymeworks
ZYME
$2.05B
$39.7M 0.27%
852,200
+302,200
+55% +$10.4M
AGIO icon
68
Agios Pharmaceuticals
AGIO
$1.98B
$37.9M 0.26%
1,083,429
-166,571
-13% -$7.3M
LNTH icon
69
Lantheus
LNTH
$6.53B
$33.6M 0.23%
2,650,000
+15,001
+0.6% +$206K
GBT
70
DELISTED
Global Blood Therapeutics, Inc.
GBT
$33.1M 0.23%
+600,000
New +$38.1M
ZNTL icon
71
Zentalis Pharmaceuticals
ZNTL
$363M
$32.4M 0.22%
991,174
– –
TVRD
72
Tvardi Therapeutics
TVRD
$24.8M
$28.6M 0.2%
62,500
-1,389
-2% -$807K
NVTA
73
DELISTED
Invitae Corporation
NVTA
$25.7M 0.18%
593,472
-63,056
-10% -$2.15M
RDUS
74
DELISTED
Radius Health, Inc.
RDUS
$23.9M 0.17%
2,107,400
+7,400
+0.4% +$91.5K
BRMK
75
CALL
DELISTED
Broadmark Realty Capital Inc. Common Stock
BRMK
$23.6M 0.16%
2,391,536
– –
1 2
3
4 5

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q3 2020 Portfolio in Review

As of Q3 2020, Thomas Steyer held 146 positions worth $14.5B, up 16% from $12.5B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Thomas Steyer deployed $582M of net new capital in Q3 2020, opening 31 new positions and adding to 52 existing holdings. Its largest new stake was Boston Scientific: 8,275,919 shares worth $316M.

By sector, the portfolio is most concentrated in Healthcare at 45% of assets, up from 43% a quarter earlier, followed by Communication Services and Technology.

On the sell side, the largest reduction was Salesforce, an estimated $181M trimmed.

  • Thomas Steyer's largest Q3 2020 buy was Boston Scientific: 8,275,919 shares worth $316M.
  • Thomas Steyer added most to Alphabet (Google) Class C in Q3 2020, an estimated $216M increase.
  • Thomas Steyer's biggest Q3 2020 reduction was Salesforce, cutting an estimated $181M.
  • Thomas Steyer fully exited People Inc in Q3 2020, selling an estimated $456M.
  • Thomas Steyer's ten largest holdings make up 32% of its $14.5B portfolio in Q3 2020.
  • Thomas Steyer opened 31 new positions and closed 24 in Q3 2020.
  • Thomas Steyer's portfolio value rose 16% quarter-over-quarter to $14.5B.

Based on Farallon Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.